FDA is working to gather product recall information from these companies and has removed them from the list of products that are not impacted by this recall:It is possible that not all valsartan-containing products repackaged by these companies are impacted by the recall. We are contacting prescribers whose patients are taking valsartan tablets to obtain prescriptions for an alternate medicine. Drug interactions are reported among people who take Losartan and Clonidine together.

Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication. pharmaceutical manufacturers not affiliated with CVS Caremark. The study is created by eHealthMe based on reports of 2,559 people who take Losartan and Clonidine from the FDA, and is updated regularly. or redistributed. Find out which specific blood pressure medications are affected by the recall.

Currently, the recall affects only medications containing valsartan, losartan, or irbesartan. The fourth was announced in April.For more about the newly recalled lots, read the pharmaceutical company's announcement at Stay up-to-date on the biggest health and wellness news with our weekly recap.This material may not be published, broadcast, rewritten, or redistributed. On eHealthMe, you can check real-world data from 16 million patients, and personalize the results to your gender and age. Torrent Pharmaceuticals Ltd. has expanded its recall of losartan potassium and losartan potassium/hydrochlorothiazide tablets. View CVS/pharmacy drug recalls, safety alerts and market withdrawal lists. If a manufacturer detects new or higher levels of impurity, they should take action to prevent changes to the product’s safety profile.

... losartan telmisartan valsartan EDARBI -Antiarrhythmics amiodarone disopyramide flecainide mexiletine ... clonidine guanfacine hydralazine isoxsuprine methyldopa minoxidil prazosin reserpine BIDIL CORLANOR RANEXA

Fox News Flash top headlines for Sept. 24 are here. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification.To date, Torrent Pharmaceuticals Limited has not received any reports of adverse events related to this recall.Valsartan is used to control high blood pressure and for the treatment of heart failure. FDA has product recall information from two additional In addition, FDA has indicated that the following additional repackagers are recalling or are expected to recall valsartan-containing products. Download it now:Refill prescriptions (mail service only) without creating an account.Download a form to start a new mail order prescription. The companies impacted are recalling all lots of non-expired products that contain the ingredient valsartan supplied to them by Zhejiang Huahai Pharmaceuticals, Linhai, China.

Patients who are on valsartan should continue taking their medication, as the risk of harm to the patient's health may be higher if the treatment is stopped immediately without any alternative treatment.On August 14, 2018, AvKare announced a patient-level recall of all valsartan tablets that were previously recalled by Camber and packaged under the AvKare/AvPak labelOn August 9, 2018, Camber Pharmaceuticals, Inc. announced a FDA continues to evaluate valsartan-containing products and has updated the FDA is working with drug manufacturers to ensure future valsartan active pharmaceutical ingredients (APIs) are not at risk of NDMA formation. CVS Caremark is in the process of contacting patients and prescribers to advise them of this recall. The company said the recall only affects products found to have more than the FDA-allowable amount of NMBA.“Patients who are taking Losartan Potassium Tablets, USP and Losartan Potassium/Hydrochlorothiazide Tablets, USP should continue taking their medication, as the risk of harm to the patient’s health may be higher if the treatment is stopped immediately without any alternative treatment,” the FDA said, advising patients to contact their pharmacist or doctor about an alternative medication.The news marks the fifth time the company has expanded the recall. All market data delayed 20 minutes.

For more information, please call the FDA at 1‑888‑INFO‑FDA (1‑888‑463‑6332) or visit https://www.fda.gov/Drugs/DrugSafety/ucm613916.htm.

Check out what's clicking on Foxnews.comTorrent Pharmaceuticals Limited has again expanded a More specifically, the expanded recall includes “an additional 3 lots of Losartan Potassium Tablets USP and 2 lots of Losartan Potassium/Hydrochlorothiazide Tablets, USP,” the FDA said in a statement.The ingredient detected in the tablets was identified as N-Methylnitrosobutyric acid (NMBA), a known animal and potential human carcinogen. In combination with amlodipine plus hydrochlorothiazide, it is used to control high blood pressure. ©2020 FOX News Network, LLC. All rights reserved. On July 27, 2018, FDA posted updated information regarding the valsartan recalls. Zhejiang Huahai has stopped distributing its valsartan API and the FDA is working with the affected companies to reduce or eliminate the valsartan API impurity from future products.A complete list of the affected products is provided For more information, please call the FDA at 1‑888‑INFO‑FDA (1‑888‑463‑6332) or visit For contact information for the drug manufacturers involved, please see below:The CVS/caremark™ app lets you manage your prescription benefits on the go. All market data delayed 20 minutes.Madeline Farber is a Reporter for Fox News. All rights reserved.

They also expanded the previous recall of Valsartan/Amlodipine/HCTZ tablets to include all lots.Torrent Pharmaceuticals Limited is voluntarily recalling 14 lots of Valsartan/Amlodipine/HCTZ tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. However, not all lots of these medications are affected and being recalled.

In a Sept. 19 statement, the Food and Drug Administration (FDA) announced Torrent Pharmaceuticals Limited voluntarily expanded the recall to include additional lots …